Gaucher disease and bone

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 5, 2011, Pages 665-681

  Mikosch, P ^a,b  

^a HANUSCH HOSPITAL   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Bone crisis; Bone involvement; Erlenmeyer flask deformity; Fracture; Gaucher disease; Lysosomal storage disorders; Osteomyelitis; Osteonecrosis; Osteoporosis; Pain

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; COLECALCIFEROL; COLONY STIMULATING FACTOR 1; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; DENOSUMAB; ELIGLUSTAT; GLUCOSYLCERAMIDASE; IMIGLUCERASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MIGLUSTAT; PARATHYROID HORMONE; PROPROSTAGLANDIN E2; PROSTAGLANDIN E2; PROTEIN PRECURSOR; RALOXIFENE; STRONTIUM RANELATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELAGLUCERASE ALFA;

ARTHROPLASTY; ARTICLE; AVASCULAR NECROSIS; BONE ATROPHY; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL FEATURE; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME REPLACEMENT; ENZYME SUBSTRATE; FRACTURE; GAUCHER DISEASE; GENE MUTATION; HUMAN; INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SPLENECTOMY; TREATMENT OUTCOME; REVIEW;

BONE DISEASES; GAUCHER DISEASE; HUMANS;

EID: 82955235006     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.10.015     Document Type: Review

References (96)

1. Gaucher P. De l' epithelioma primitive de la rate, hypertrophic idiopathique de la rate sans leucemie (doctoral thesis), Paris; 1882.
2. O.A. Bodamer, and C. Hung Laboratory and genetic evaluation of Gaucher disease Wien Med Wschr 160 2010 600 604
3. A. Mehta Epidemiology and natural history of Gaucher's disease Eur J Intern Med 17 2006 S2 S5
4. G.M. Pastores Neuropathic Gaucher disease Wien Med Wschr 160 2010 605 608
5. Walton-Bowen K, Mantick N. Gaucher registry annual aggregate data report; 2000.
6. D.P. Germain Gaucher's disease: a paradigm for interventional genetics Clin Genet 65 2004 77 86 (Pubitemid 38220108)
7. D.A. Hughes, and G.M. Pastores The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches Wien Med Wschr 160 2010 594 599
8. P. Mikosch, and D.A. Hughes An overview on bone manifestations in Gaucher disease Wien Med Wschr 160 2010 609 624
9. M.J. Allen, B.J. Meyer, and A.M. Khokher Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10 QJM 90 1997 19 25 (Pubitemid 27075848)
10. V. Barak, M. Acker, and B. Nisman Cytokines in Gaucher's disease Eur Cytokine Netw 10 1999 205 210 (Pubitemid 29332776)
11. C.E. Hollak, L. Evers, and J.M. Aerts Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease Blood Cells Mol Dis 23 1997 201 212 (Pubitemid 27469455)
12. M. Yoshino, Y. Watanabe, and Y. Tokunaga Roles of specific cytokines in bone remodelling and hematopoisis in Gaucher disease Pediatr Int 49 2007 959 965 (Pubitemid 350197159)
13. M. Lichtenstein, A. Zimran, and M. Horowitz Cytokine mRNA in Gaucher disease Blood Cells Mol Dis 23 1997 395 401 (Pubitemid 28123721)
14. P.M. Campeau, M. Rafei, and M.N. Boivin Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome Blood 114 2009 3134 3135
15. M. Abe, K. Hiura, and J. Wilde Role for macrophage inflammatory protein (MIP)-1α and MIP-1ß in the development of osteolytic in multiple myeloma Blood 100 2002 2195 2302
16. M.J. Breemen, M. de Fost, and J.S. Voerman Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease Biochim Biophys Acta 1772 2007 788 796 (Pubitemid 46891215)
17. L. Lacerda, F.A. Arosa, and R. Lacerda T cell numbers relate to bone involvement in Gaucher disease Blood Cells Mol Dis 25 1999 130 138 (Pubitemid 29298192)
18. W. Sipos, P. Pietschmann, and M. Rauner Pathophysiology of osteoporosis Wien Med Wschr 159 2009 230 234
19. D.W. Stowens, S.L. Teitelbaum, and A.J. Kahn Skeletal complications of Gaucher disease Medicine 64 1985 310 322 (Pubitemid 16224046)
20. C. Drugan, G. Jebeleanu, and P. Grigorescu-Sido Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease Blood Cells Mol Dis 28 2002 13 20 (Pubitemid 34408983)
21. G. Ciana, C. Martini, and A. Leopaldi Bone marker alterations in patients with type 1 Gaucher disease Calcif Tissue Int 72 2003 185 189 (Pubitemid 36919522)
22. G. Ciana, R. Addobbati, and G. Tamaro Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy J Inherit Metab Dis 28 2005 723 732 (Pubitemid 41349260)
23. K.B. Sims, G.M. Pastores, and N.J. Weinreb Improvement of bone disease by imiglucerase (Cerecyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study Clin Genet 73 2008 430 440 (Pubitemid 351517258)
24. R. Schiffmann, H. Mankin, and J.M. Dambrosia Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy Blood Cells Mol Dis 28 2002 288 296 (Pubitemid 34743762)
25. C.E. Fiore, R. Barone, and P. Pennisi Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease J Bone Miner Metab 20 2002 24 38
26. M.S. Parisi, S.R. Mastaglia, and A. Bagur Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase Eur J Med Res 13 2008 31 38 (Pubitemid 351227761)
27. P. Mikosch, M. Reed, and R. Baker Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat Calcif Tissue Int 83 2008 43 54
28. Van Dussen, P. Lips, and V.E. Everts Markers of bone turnover in Gaucher disease: Modeling the evolution of bone J Clin Endocrinol Metab May 4 2011 [Epub ahead of print]
29. P.K. Mistry, J. Liu, and M. Yang Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage Proc Natl Acad Sci USA 107 2010 19,473 19,478 [Epub 2010 Oct 20]
30. M.T. Moran, J.P. Schofield, and A.R. Hayman Pathologic gene expresion in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K Blood 96 2000 1969 1978 (Pubitemid 30662113)
31. I. Magal, E. Lebel, and G. Altarescu Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease Br J Haematol 133 2006 93 97 (Pubitemid 43327203)
32. P. Mikosch, M. Reed, and H. Stettner Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry Mol Genet 96 2009 113 120
33. R.J. Wentrup, M. Roca-Espiau, and N.J. Weinreb Skeletal aspects of Gaucher disease: a review Br J Radiol 75 SUPPL.. 1 2002 A2 A12
34. S. Piran, A. Roberts, and M.A. Patterson The clinical course of untreated Gaucher disease in 22 patients over 10 years: haematological and skeletal manifestations Blood Cells Mol Dis 43 2009 289 293
35. P. Giraldo, V. Salano, and J.I. Perez-Calvo Spanish Group on Gaucher Disease. Quality of life to type 1 Gaucher disease: Spanish experience Qual Life Res 14 2005 453 462 (Pubitemid 40576395)
36. B. Bembi, G. Ciana, and E. Mengel Bone complications in children with Gaucher disease Br J Radiol 75 SUPPL.. 1 2002 A37 A44
37. P.G. Sido, C. Drugan, and V. Cret Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience J Inherit Metab Dis 30 2007 783 789 (Pubitemid 47559891)
38. M.A. Faden, D. Krakow, and F. Ezgu The Erlenmeyer flask bone deformity in the skeletal dysplasias Am J Med Gen A 149A 2009 1334 1345
39. G. Pastores, S. Wallenstein, and R.J. Desnick Bone density in Type 1 Gaucher disease J Bone Min Res 11 1996 1801 1807 (Pubitemid 26367692)
40. M. Watanabe, M. Yanagisawa, and S. Sonobe An adult form of Gaucher's disease with a huge tumour formation of the right tibia Int Orthop 8 1984 195 202 (Pubitemid 15125130)
41. H. Ozturk, M. Unsal, and U. Aydingoz Pseudotumor formation in tibia in Gaucher's disease Eur J Radiol 26 1998 284 286 (Pubitemid 28168348)
42. G. Hermann, R. Shapiro, and F. Abdelwahab Extraosseous extension of Gaucher cell deposits mimicking malignancy Skelet Radiol 23 1994 253 256 (Pubitemid 24155861)
43. L.W. Poll, J.A. Koch, and S. vom Dahl Type I Gaucher disease: extraosseous extension of skeletal disease Skeletal Radiol 29 2000 15 21 (Pubitemid 30156378)
44. L.W. Poll, J.A. Koch, and S. vom Dahl Extraosseous manifestation of Gaucher's disease type I: MR and histological appearance Eur Radiol 10 2000 1660 1663
45. S. Vom Dahl, L. Poll, and M. Di Rocco Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients Curr Med Res Opin 22 2006 1045 1064 (Pubitemid 44000726)
46. M. Maas, L.W. Poll, and M.R. Terk Imaging and quantifying skeletal involvement in Gaucher disease Br J Radiol 75 SUPPL.. 1 2002 A13 A24
47. C. Hollak, M. Maas, and E. Akkerman Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme SUPPL.ementation therapy in type 1 Gaucher disease Blood Cells Mol Dis 27 2001 1005 1012 (Pubitemid 34163969)
48. M. Maas, C.E. Hollak, and E.M. Akkermann Quantification of skeletal involvement in adults with type 1 Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter Am J Roentgenol 179 2002 961 965
49. M. Maas, C. van Kuijk, and J. Stoker Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging - initial experience Radiology 229 2003 554 561 (Pubitemid 37310846)
50. M. Roca, J. Mota, and P. Alfonso S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease Eur J Radiol 52 2007 132 137 (Pubitemid 46413626)
51. E.J. Vlieger, M. Maas, and E.M. Akkerman Vertebral disc ration as a parameter for bone marrow involvement J Comput Assit Tomogr 26 2002 843 848
52. L.W. Poll, J.A. Koch, and S. vom Dahl Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results Skelet Radiol 30 2001 496 503 (Pubitemid 32894331)
53. L.W. Poll, M. Maas, and M.R. Terk Response of Gaucher bone disease to enzyme replacement therapy Br J Radiol 75 SUPPL.. 1 2002 A25 A36
54. P.L. Robertson, M. Maas, and J. Goldblatt Semiquantitive assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score AJR Am J Roentgenol 188 2007 1521 1528 (Pubitemid 46866853)
55. P. Giraldo, P. Alfonso, and K. Atutxa Real-world clinical experience with long term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project Haematologica 94 2009 1771 1775
56. M. Mass, T. Hangartner, and G. Mariani Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease Skelet Radiol 37 2008 185 188
57. P. Mikosch, S. Kohlfürst, and H.J. Gallowitsch Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? Nuklearmedizin 47 2008 239 247
58. T.R. Bilchik, and S. Heyman Skeletal scintigraphy of pseudo-osteomyelitis in Gaucher's disease. Two case reports and a review of the literature Clin Nucl Med 17 1992 279 282
59. G. Mariani, M. Filocamo, and F. Giona Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi J Nucl Med 44 2003 1253 1262 (Pubitemid 39655185)
60. G. Mariani, N. Molea, and L. La Civita Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease Eur J Nucl Med 23 1996 466 470
61. G. Mariani, and P.A. Erba Radionuclide evaluation of Gaucher disease T. Futerman, A. Zimran, Gaucher disease 2007 CRC Press Boca Raton, FL 283 315
62. N.J. Weinreb, M.C. Aggio, and H.C. Andersson International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients Semin Hematol 41 SUPPL.. 5 2004 15 22 (Pubitemid 39311678)
63. J. Charrow, J.A. Esplin, and T.J. Gribble Gaucher disease - recommendations on diagnosis, evaluation and monitoring Arch Intern Med 158 1998 1754 1760 (Pubitemid 28421418)
64. Beck M, vom Dahl S, Mengel E, et al. Leitlinie zu Morbus Gaucher. Arbeitsgemeinschaft für Pädiatrische Speichererkrankungen in der Deutschen Gesellschaft für Kinder- und Jugendmedizin. Available from: www.aps-med.de.
65. A.B. Mehta, S. Lewis, and C. Laverey Treatment of lysosomal storage disorders BMJ 327 2003 462 463 (Pubitemid 37056191)
66. G.M. Pastores, N.J. Weinreb, and H. Aerts Therapeutic goals in the treatment of Gaucher disease Semin Hematol 41 2004 4 14 (Pubitemid 39311677)
67. G.A. Grabowski, N.W. Barton, and G. Pastores Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources Ann Intern Med 122 1995 33 39
68. D. Elstein, A. Abrahamov, and I. Hadas-Halpern Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease QJM 91 1998 483 488 (Pubitemid 28325347)
69. C.E. Hollak, J.M. Aerts, and R. Goudsmit Individualised low-dose alglucerase therapy for type 1 Gaucher disease Lancet 345 1995 1474 1478
70. G.M. Pastores, A.R. Sibille, and G.A. Grabowski Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months Blood 82 1993 408 416 (Pubitemid 23206103)
71. M. de Fost, C.E. Hollak, and J.E. Groener Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 2006 850 855
72. J. Tóth, F.Z. Szücs, and K. Benkö Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI Orv Hetil 144 2003 749 755
73. J. Charrow, B. Dulisse, and G.A. Grabowski The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease Clin Genet 71 2007 205 211 (Pubitemid 46322658)
74. N.J. Weinreb, J. Charrow, and H.C. Andersson Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry Am J Med 113 2002 112 129
75. N. Weinreb, J. Barranger, and S. Packman Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease Clin Genet 71 2007 576 588 (Pubitemid 46831953)
76. R.J. Wenstrup, K.A. Kacena, and P. Kaplan Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease J Bone Miner Res 21 2007 119 126 (Pubitemid 46032604)
77. E. Lebel, A. Dweck, and A.J. Foldes Bone density changes with enzyme therapy in Gaucher disease J Bone Miner Metab 22 2004 597 601 (Pubitemid 39517881)
78. B. Bembi, M. Zanatta, and M. Carrozzi Enzyme replacement treatment in type 1 and type 3 Gaucher's disease Lancet 344 1994 1679 1682 (Pubitemid 24371101)
79. H. Andersson, P. Kaplan, K. Kacena, and J. Yee Eight-year outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1 Pediatrics 122 2008 1182 1190
80. P. Giraldo, P. Latre, and P. Alfonso Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease Haematologica 91 2006 703 706 (Pubitemid 43799475)
81. D. Elstein, C. Hollak, and J.M. Aerts Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J Inherit Metab Dis 27 2004 757 766 (Pubitemid 39433603)
82. G.M. Pastores, N.L. Barnett, and E.H. Kolodny An open-label, non-comparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther 27 2005 1215 1227 (Pubitemid 41393915)
83. G. Pastores, D. Elstein, and M. Hrebicek Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies Clin Ther 29 2007 1645 1654 (Pubitemid 47494543)
84. Peterschmitt J, Lukina E, Watman NP, et al. Genz-112638 for Gaucher disease type 1: phase 2 clinical trial results after 18 months of treatment. 51st ASH annual meeting and exposition, Abstract 1349. New Orleans; December 2009.
85. L. Osterle, T. Warner, and P.J. Meunier Treatment of type 1 Gaucher's disease affecting bone with aminohydroxy propylidene bisphosphonate (pamidronate) Q J Med 79 1991 503 515
86. R. Samuel, K. Katz, and S.E. Papapoulos Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease Pediatrics 94 1994 385 389 (Pubitemid 24271485)
87. B. Bembi, E. Agosti, and P. Boehm Aminohydroxypropylidene-bisphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3 Acta Paediatr 83 1994 122 124 (Pubitemid 24072097)
88. G. Ciana, M. Cuttini, and B. Bembi Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement N Engl J Med 337 1997 712 (Pubitemid 27375485)
89. R.J. Wenstrup, L. Bailey, and G.A. Grabowski Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy Blood 104 2004 1253 1257 (Pubitemid 39166496)
90. K.F. Lutsky, and N.C. Tejwani Orthopaedic manifestations of Gaucher disease Bull NYU Hosp Jt Dis 65 2007 37 42 (Pubitemid 46427664)
91. R.M. Javier, and E. Hachulla Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment Presse Med 36 2007 1971 1984 (Pubitemid 350122938)
92. E. Lebel, M. Phillips, and D. Elstein Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease Acta Orthop 80 2009 201 204
93. P. Mattsson, and S. Larsson Stability of internally fixed femoral neck fractures augmented with resorbable cement. A prospective randomized study using radiostereometry Scand J Surg 92 2003 215 219 (Pubitemid 37271156)
94. R.F. DeMayo, A.H. Haims, and M.C. McRae Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher's disease AJR 191 2008 115 123 (Pubitemid 351955212)
95. H. Ida, O.M. Rennert, and S. Kato Severe skeletal complications in Japanese patients with type 1 Gaucher disease J Inherit Metab Dis 22 1999 63 73 (Pubitemid 29078132)
96. M. Beck Villa Metabolica - a center of excellence for the diagnosis and treatment of lysosomal storage disorders Wien Med Wschr 160 2010 625 626